A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration

Balwinder Singh; John D. Port; Jennifer L.Vande Voort; Brandon J. Coombes; Jennifer R. Geske; Ian R. Lanza; Robert J. Morgan; Mark A. Frye

doi:10.1016/j.psychres.2021.113953

A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration

Balwinder Singh, John D. Port, Jennifer L.Vande Voort, Brandon J. Coombes, Jennifer R. Geske, Ian R. Lanza, Robert J. Morgan, Mark A. Frye

Research output: Contribution to journal › Article › peer-review

Abstract

Gamma-aminobutyric acid (GABA) and glutamate neurotransmission have been implicated in the pathophysiology of depression and mechanistically linked to ketamine's antidepressant response. Seven patients with treatment-resistant depression enrolled in an open-label, feasibility trial of a single IV 40-min ketamine infusion during a functional MR spectroscopy (fMRS) scan utilizing a novel frequency adjusting MEGA-PRESS sequence. Next-day treatment remission and reduction in the MADRS scores correlated with anterior cingulate cortex peak GABA levels. These novel findings provide further insights into the underlying neurobiological mechanisms of ketamine and, if confirmed in larger studies, would be encouraging for further development of GABAergic biomarker associated with ketamine response.

Original language	English (US)
Article number	113953
Journal	Psychiatry Research
Volume	301
DOIs	https://doi.org/10.1016/j.psychres.2021.113953
State	Published - Jul 2021

Keywords

Anterior cingulate cortex
GABA
Treatment-resistant depression

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Access to Document

10.1016/j.psychres.2021.113953

Cite this

@article{7b2ddf13813b41449af9b4ae9d4073c4,

title = "A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration",

abstract = "Gamma-aminobutyric acid (GABA) and glutamate neurotransmission have been implicated in the pathophysiology of depression and mechanistically linked to ketamine's antidepressant response. Seven patients with treatment-resistant depression enrolled in an open-label, feasibility trial of a single IV 40-min ketamine infusion during a functional MR spectroscopy (fMRS) scan utilizing a novel frequency adjusting MEGA-PRESS sequence. Next-day treatment remission and reduction in the MADRS scores correlated with anterior cingulate cortex peak GABA levels. These novel findings provide further insights into the underlying neurobiological mechanisms of ketamine and, if confirmed in larger studies, would be encouraging for further development of GABAergic biomarker associated with ketamine response.",

keywords = "Anterior cingulate cortex, GABA, Treatment-resistant depression",

author = "Balwinder Singh and Port, {John D.} and Voort, {Jennifer L.Vande} and Coombes, {Brandon J.} and Geske, {Jennifer R.} and Lanza, {Ian R.} and Morgan, {Robert J.} and Frye, {Mark A.}",

note = "Funding Information: This work was supported by the Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota. This publication was made possible by the Mayo Clinic CTSA through grant number UL1TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Funding Information: B Singh reports research time support from Medibio (unrelated to the current study); grant support from Clinical and Translational Science (CCaTS) Small Grants Award, and Mayo Clinic. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = jul,

doi = "10.1016/j.psychres.2021.113953",

language = "English (US)",

volume = "301",

journal = "Psychiatry Research",

issn = "0165-1781",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration

AU - Singh, Balwinder

AU - Port, John D.

AU - Voort, Jennifer L.Vande

AU - Coombes, Brandon J.

AU - Geske, Jennifer R.

AU - Lanza, Ian R.

AU - Morgan, Robert J.

AU - Frye, Mark A.

N1 - Funding Information: This work was supported by the Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota. This publication was made possible by the Mayo Clinic CTSA through grant number UL1TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Funding Information: B Singh reports research time support from Medibio (unrelated to the current study); grant support from Clinical and Translational Science (CCaTS) Small Grants Award, and Mayo Clinic. Publisher Copyright: © 2021 Elsevier Ltd

PY - 2021/7

Y1 - 2021/7

N2 - Gamma-aminobutyric acid (GABA) and glutamate neurotransmission have been implicated in the pathophysiology of depression and mechanistically linked to ketamine's antidepressant response. Seven patients with treatment-resistant depression enrolled in an open-label, feasibility trial of a single IV 40-min ketamine infusion during a functional MR spectroscopy (fMRS) scan utilizing a novel frequency adjusting MEGA-PRESS sequence. Next-day treatment remission and reduction in the MADRS scores correlated with anterior cingulate cortex peak GABA levels. These novel findings provide further insights into the underlying neurobiological mechanisms of ketamine and, if confirmed in larger studies, would be encouraging for further development of GABAergic biomarker associated with ketamine response.

AB - Gamma-aminobutyric acid (GABA) and glutamate neurotransmission have been implicated in the pathophysiology of depression and mechanistically linked to ketamine's antidepressant response. Seven patients with treatment-resistant depression enrolled in an open-label, feasibility trial of a single IV 40-min ketamine infusion during a functional MR spectroscopy (fMRS) scan utilizing a novel frequency adjusting MEGA-PRESS sequence. Next-day treatment remission and reduction in the MADRS scores correlated with anterior cingulate cortex peak GABA levels. These novel findings provide further insights into the underlying neurobiological mechanisms of ketamine and, if confirmed in larger studies, would be encouraging for further development of GABAergic biomarker associated with ketamine response.

KW - Anterior cingulate cortex

KW - GABA

KW - Treatment-resistant depression

UR - http://www.scopus.com/inward/record.url?scp=85104924190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104924190&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2021.113953

DO - 10.1016/j.psychres.2021.113953

M3 - Article

C2 - 33933839

AN - SCOPUS:85104924190

SN - 0165-1781

VL - 301

JO - Psychiatry Research

JF - Psychiatry Research

M1 - 113953

ER -

A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this